Alex Lenz

FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018.

FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018.

FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018.

FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018.

FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018.